Wave Life Sciences Ltd. (WVE)

NASDAQ: WVE · IEX Real-Time Price · USD
4.24
+0.06 (1.44%)
Mar 21, 2023, 4:00 PM EDT - Market closed
1.44%
Market Cap 368.50M
Revenue (ttm) 4.18M
Net Income (ttm) -152.90M
Shares Out 86.91M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 416,806
Open 4.18
Previous Close 4.18
Day's Range 3.99 - 4.31
52-Week Range 1.16 - 7.12
Beta -0.87
Analysts Buy
Price Target 8.16 (+92.45%)
Earnings Date Mar 22, 2023

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2015
Employees 235
Stock Exchange NASDAQ
Ticker Symbol WVE
Full Company Profile

Financial Performance

In 2021, WVE's revenue was $40.96 million, an increase of 104.03% compared to the previous year's $20.08 million. Losses were -$122.25 million, -18.45% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 92.45% from the latest price.

Price Target
$8.16
(92.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

2 weeks ago - GlobeNewsWire

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)

Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e...

1 month ago - Zacks Investment Research

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

1 month ago - GlobeNewsWire

All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Other symbols: CABAVRNA
2 months ago - Zacks Investment Research

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

3 months ago - Zacks Investment Research

Wave, GSK enter strategic collaboration

Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to devel...

Other symbols: GSK
3 months ago - Market Watch

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties

3 months ago - GlobeNewsWire

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CS...

4 months ago - GlobeNewsWire

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

4 months ago - GlobeNewsWire

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

4 months ago - GlobeNewsWire

Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...

5 months ago - Zacks Investment Research

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

Six presentations and posters between OTS and ESGCT meetings will highlight Wave's oligonucleotide chemistry advancements as well as RNA editing and RNAi capabilities

6 months ago - GlobeNewsWire

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver...

6 months ago - GlobeNewsWire

Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

6 months ago - GlobeNewsWire

Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

6 months ago - Zacks Investment Research

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and f...

6 months ago - GlobeNewsWire

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023;  first-in-class RNA editing candidate and most advanced program currently in development usin...

7 months ago - GlobeNewsWire

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

8 months ago - GlobeNewsWire

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

10 months ago - GlobeNewsWire